AMYLOID BETA PROTEIN IN CSF AND FAMILIAL AGGREGATION IN ALZHEIMER'S DISEASE

脑脊液中Abeta的存在具有许多令人兴奋的意义 了解阿尔茨海默氏症。尽管已经收集的数据使它 脑脊液中的Abeta不太可能成为阿尔茨海默氏症的诊断试验 尽管如此，它可能有助于阐明一些 疾病中存在的异质性。具体地说，这其中的一个目标 研究旨在确定阿尔茨海默病的先证者是否具有更高的 Abeta浓度与一种不同的疾病有一级亲属 阿尔茨海默病的风险比一级亲属或先证者 较低浓度的Abeta，或者，无论年龄 在一级亲属中起病的进行性痴呆症可能是 以脑脊液Abeta浓度区分。为了实现这些目标，证金公司 将从阿尔茨海默氏症患者那里获得一级 亲属评估将通过家族史的方法来确定 阿尔茨海默病和相关痴呆的发病率，以及 开始了。 脑脊液Abeta将在凯斯史蒂文·杨金的实验室进行检测 西部保护区。杨金博士目前的抗体识别出40，41，42 Abeta多肽的43个氨基酸序列。然而，在凯斯工作 西部储备银行将致力于开发一种特定的抗体， 可以区分40个氨基酸序列与41个和42个氨基酸序列，以确定 任何一种序列都比对组合的4 kDa的测量更具启发性 蛋白质。

The presence of Abeta in CSF has a number of exciting implications for understanding Alzheimer's disease. Although data already gathered makes it highly unlikely that Abeta in CSF will be a diagnostic test for Alzheimer's disease, it may nonetheless, be useful in elucidating some of the heterogeneity that exists in the disease. Specifically, one goal of this study is to determine whether Alzheimer's disease probands with higher concentrations of Abeta have first degree relatives with a different morbid risk for Alzheimer's disease than the first degree relatives or probands with a lower concentration of Abeta, or alternatively, whether the age of onset of progressive dementia in first degree relatives can be differentiated by CSF Abeta concentrations. To achieve these goals, CSF will be obtained from Alzheimer's patients in whom the first degree relatives will be evaluated through the family history method to determine the incidence of Alzheimer's disease and related dementias, and age of onset. CSF Abeta will be measured in the laboratory of Steven Younkin at Case Western Reserve. Dr. Younkin's current antibody identifies the 40,41,42 and 43 amino acid sequences of Abeta peptides. However, work at Case Western Reserve will be directed toward developing a specific antibody that can differentiate the 40 vs. 41 and 42 amino acid sequences to determine if either sequence is more revealing than measurements of the combined 4kDa proteins.